Opinion|Videos|January 10, 2025
CAR-T Therapy: Approach to Bridging
Panelists explain how CAR-T cell therapy works and describe the treatment process, discussing whether CAR -T is considered a complex procedure at their institution or if the logistics have been streamlined into clinical workflows, and they also detail their institution's approach to bridging therapy for patients awaiting CAR-T manufacturing and infusion, including whether patients are managed in-house or sent back to community centers.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Could you explain how CAR-T cell therapy works and describe the treatment process?
- Do you consider CAR-T therapy a complex process at your institution, or have you been able to streamline the logistics and integration into clinical workflows?
- Can you explain your institution's approach to bridging therapy for patients awaiting CAR-T manufacturing and infusion?
- Do you send patients back to community centers or is does it the treatment happen done in-house?
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
Advertisement
Advertisement
Trending on CancerNetwork
1
Setting Up an HDR Brachytherapy Program Amid a National Decline
2
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
5